| First Author | Zumla A | Year | 2016 |
| Journal | Nat Rev Drug Discov | Volume | 15 |
| Issue | 5 | Pages | 327-47 |
| PubMed ID | 26868298 | Mgi Jnum | J:283999 |
| Mgi Id | MGI:6390641 | Doi | 10.1038/nrd.2015.37 |
| Citation | Zumla A, et al. (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15(5):327-47 |
| abstractText | In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract infections, such as the common cold. By contrast, the CoVs responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which were discovered in Hong Kong, China, in 2003, and in Saudi Arabia in 2012, respectively, have received global attention over the past 12 years owing to their ability to cause community and health-care-associated outbreaks of severe infections in human populations. These two viruses pose major challenges to clinical management because there are no specific antiviral drugs available. In this Review, we summarize the epidemiology, virology, clinical features and current treatment strategies of SARS and MERS, and discuss the discovery and development of new virus-based and host-based therapeutic options for CoV infections. |
